MAPT and Alzheimer disease: In AD patients, MAPT mRNA levels were not significantly higher in either area (Fig. 4A), but were associated with low levels of transcripts initiated by promoter A in both regions (p = 0.0002 and p = 0.003, after Dunnett’s adjustment for multiple comparisons) (Fig. 4B).